1875.HK BioDlink +16.48% to HK$5.23 on 20 Mar 2026 market closed: outlook

BioDlink International (1875.HK) led Hong Kong healthcare gainers after a 16.48% jump to HK$5.23 on 20 Mar 2026 as the market closed. The 1875.HK stock move came on heavy volume of 13,704,000 shares, versus an average of 3,314,345. Traders cited sector momentum and company-specific interest in oncology pipelines. We break down the drivers, valuation, technicals and what Meyka AI’s model projects for the stock going forward.

1875.HK stock: intraday price action and volume

BioDlink (1875.HK) opened at HK$4.49 and hit a day high of HK$5.28 before settling at HK$5.23. Volume exploded to 13,704,000, a relative volume of 4.13 times the average. The surge pushed the stock to its year high of HK$5.28, up from a year low of HK$1.52 and well above the 50-day average HK$4.01 and 200-day average HK$2.59.

Drivers and recent news behind the rise

Market chatter links the move to renewed interest in BioDlink’s oncology pipeline and coverage updates in financial feeds. Reuters flagged live quotes and charting for 1875.HK, while Investing.com shows peer comparisons that highlight improving sector metrics. See Reuters and Investing.com for raw feeds: Reuters and Investing.com.

Valuation snapshot and financial metrics for 1875.HK stock

At HK$5.23, BioDlink’s market capitalisation reads HK$3,792,780,582 and reported EPS is HK$0.02, giving a trailing PE of 261.50 on quoted figures. Key ratios show a current ratio 2.05, PB ~5.33, and price-to-sales ~4.49. Revenue per share TTM is HK$1.03 and net income per share TTM is -HK$0.14, signalling clinical-stage investment weight versus near-term profits.

Technical view: momentum and overbought signals

Technicals show strong momentum. RSI is 80.39 and ADX is 68.75, indicating a robust uptrend but overbought conditions. Bollinger upper band sits near HK$4.76 while the stock closed above that band. Short-term traders should note MFI 86.64 and CCI 258.58, which point to a potential pullback or consolidation after a sharp run.

Meyka Grade & Forecast for 1875.HK stock

Meyka AI rates 1875.HK with a score out of 100: 70.22/100, Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 5-year price of HK$6.45, versus the current HK$5.23, implying an upside of 23.21%. Forecasts are model-based projections and not guarantees.

Risks and catalysts to watch for investors

Key risks include clinical trial outcomes, capital raises that could dilute shares, and high valuation metrics such as PE 261.50 and PB 5.33. Catalysts that could sustain gains are positive trial readouts for TAB008 or TA-series assets, better-than-expected R&D milestones, or sector re-rating in Hong Kong healthcare. Liquidity improved today, but volatility remains high.

Final Thoughts

1875.HK stock stood out as a top gainer on 20 Mar 2026, climbing 16.48% to HK$5.23 on volume that was more than four times average. The move reflects renewed investor interest in BioDlink’s oncology pipeline and a broader rebound in Hong Kong healthcare. Valuation is rich with a trailing PE around 261.50 and PB near 5.33, so further gains will likely need tangible clinical or commercial progress. Meyka AI’s forecast model projects a 5-year price of HK$6.45, implying +23.21% versus the current price HK$5.23. Forecasts are model-based projections and not guarantees. For traders, technical indicators show overbought signals and suggest a near-term pullback is possible. For longer-term investors, watch upcoming trial milestones, cash runway, and any capital raising terms. Use this analysis alongside primary company announcements and live feeds on Reuters and compare peers on Investing.com. Meyka AI provides this as an AI-powered market analysis platform; these notes are informational and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.